Vasorelaxing effect of levosimendan against 5-hydroxytryptamine-induced contractions in isolated human conduit bypass grafts

Authors: Pataricza, János1; Szolnoky, Jenő2; Krassói, Irén3; Hegedűs, Zoltán2; Kun, Attila1; Varró, András1; Papp, Julius G.y.4

Source: Journal of Pharmacy and Pharmacology, Volume 58, Number 8, August 2006 , pp. 1107-1112(6)

Publisher: Pharmaceutical Press

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Levosimendan is a novel inodilator drug developed for the treatment of heart failure. The possible vasodilating property of the drug in human coronary artery bypass grafts was investigated. Isometric tensions of the left internal thoracic artery (LITA, n = 8) as well as the proximal and distal segments of the radial artery (RA, n = 8 and 8) were measured in isolated organ baths. Concentration-relaxation curves for levosimendan (0.009-1.14 μmol L−1) were obtained against 5-hydroxytryptamine (5-HT; serotonin, 0.002-9.3 μmol L−1)-induced contractions. 5-HT-induced contraction of LITA was considerably smaller than that of the proximal and distal RAs. Levosimendan relaxed the grafts in the following order of calculated maximum efficacies (Emax): LITA > proximal RA > distal RA (LITA 100.3±16.2% of 5-HT-induced maximum tension, proximal RA 86.9±8.6%, distal RA 59.4±17.5%, P < 0.05 LITA vs distal RA). The potency values of levosimendan, expressed as the negative logarithm of 50% effective concentrations (pD2), were comparable in the three bypass grafts (LITA −6.52±0.44 log mol L−1, proximal RA −6.60±0.49 log mol L−1, distal RA −6.85±0.45 log mol L−1). The results suggest that levosimendan is an effective vasorelaxant of conduit bypass grafts and may serve as a new therapeutic tool, especially in the case of LITA and proximal RA grafts, for relieving perioperative spasm and subsequent graft failure.

Document Type: Research article

DOI: 10.1211/jpp.58.8.0012

Affiliations: 1: Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary 2: Division of Cardiac Surgery, 2nd Department of Internal Medicine, University of Szeged, Szeged, Hungary 3: Division of Cardiovascular Pharmacology, Hungarian Academy of Sciences, Szeged, Hungary 4: Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary; Division of Cardiovascular Pharmacology, Hungarian Academy of Sciences, Szeged, Hungary

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$38.49 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A